RecruitingPhase 3NCT06712888
Toripalimab Vs. Placebo Wtih GP Induction Chemotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma
Studying Nasopharyngeal carcinoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Sun Yat-sen University
- Intervention
- TORIPALIMAB INJECTION (JS001 ) combine with GP chemotherapy(drug)
- Enrollment
- 466 target
- Eligibility
- 18-70 years · All sexes
- Timeline
- 2025 – 2032
Study locations (1)
- Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
Collaborators
First Affiliated Hospital of Guangxi Medical University · Guangxi Medical University Cancer Center · Affiliated Hospital of Guangdong Medical University · Cancer Hospital Chinese Academy of Medical Science, Shenzhen Center · The University of Hong Kong-Shenzhen Hospital · Hunan Cancer Hospital · The Affiliated Cancer Hosipital of Guizhou Meidical University · Sichuan Cancer Hospital and Research Institute · Fujian Cancer Hospital
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06712888 on ClinicalTrials.govOther trials for Nasopharyngeal carcinoma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT06980038Testing Whether Cemiplimab (REGN2810) Plus CDX-1140 Given Prior to Surgery Are Better Than Cemiplimab (REGN2810) Alone in Patients With Stage III-IV Head and Neck CancerNational Cancer Institute (NCI)
- RECRUITINGPHASE2NCT07362979Toripalimab Combined With Different Platinum-Based Induction Chemotherapy Regimens for Locally Advanced Nasopharyngeal CarcinomaSun Yat-sen University
- RECRUITINGNANCT06796270Hypofractionated Radiotherapy for Nasopharyngeal CarcinomaThe Second Affiliated Hospital of Hainan Medical University
- RECRUITINGPHASE2NCT06059261Envafolimab Combined With Chemoradiotherapy and Recombinant Human Endostatin for LA-NPC.Chongqing University Cancer Hospital
- RECRUITINGNCT07376603IMRT Alone for Stage IB Nasopharyngeal Carcinoma Without High-Risk FeaturesQiaojuan Guo
- RECRUITINGPHASE3NCT07340515Proton vs Photon IMRT in Locally Advanced Nasopharyngeal Carcinoma: A Phase III TrialMan Hu
- RECRUITINGNCT07232680Prospective Immuno-Radiomic Profiling in Nasopharyngeal Carcinoma Treated With Proton or Photon ChemoradiotherapyCheng-En Hsieh
- RECRUITINGPHASE3NCT0732885440.2Gy Versus 49.2Gy Radiotherapy in Low-Risk Target Volume for Chemosensitive Stage II Nasopharyngeal CarcinomaMing-Yuan Chen